Emmanuel S. Antonarakis, MD

Emmanuel S. Antonarakis, MD

University of Minnesota

Minneapolis, Minnesota

Emmanuel S. Antonarakis, MD, is the Associate Director for Translational Research with the Masonic Cancer Center, and the Clark Endowed Professor of Medicine at the University of Minnesota in Minneapolis. Dr. Antonarakis’ primary research focuses on drug development and clinical trial design for patients with prostate cancer, as well as cancer genomics. His clinical interest is the management of prostate cancer and other genitourinary malignancies.

Dr. Antonarakis earned his medical degree and completed an internship at the University of Wales in Cardiff. He then completed a residency in Internal Medicine and a fellowship in Medical Oncology at Johns Hopkins Hospital in Baltimore, Maryland.

Dr. Antonarakis has additional interest in liquid biomarker development, specifically the clinical validation of the AR-V7 marker as well as DNA repair markers and their therapeutic implications. He is currently the primary investigator of several phase II and III prostate cancer trials, and is an active member of numerous professional groups and societies, including the Prostate Cancer Clinical Trials Consortium (PCCTC),the Eastern Cooperative Oncology Group-American College of Radiology Imaging Network (ECOG-ACRIN), the American Society of Clinical Investigation, the National Cancer Institute Prostate Cancer Task Force, and the National Comprehensive Cancer Network (NCCN) Prostate Cancer Panel. Dr. Antonarakis also serves on the editorial boards of several oncology journals, including the Journal of Clinical Oncology. He is the author of  over 290 peer-reviewed articles and several book chapters, and has edited a textbook about androgen receptor signaling in cancer.

Talks by Emmanuel S. Antonarakis, MD

Castration Resistant Prostate Cancer – Developments and Challenges from 2020

Castration Resistant Prostate Cancer – Developments and Challenges from 2020

| Mar 2021

In this Platinum Lecture, Emmanuel S. Antonarakis, MD, Professor of Oncology and Urology as well as Director of Prostate Cancer Medical Oncology Research and the Co-Director of the Prostate Cancer Multidisciplinary Clinic at the Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, summarizes developments from 2020 in mutation-targeted treatments for metastatic castration-resistant prostate cancer (mCRPC). He considers the successes of PARP inhibitors, especially for patients with the BRCA2 mutation, and the limitations of PD1 inhibitors. Dr. Antonarakis concludes by looking at promising research into B7-H3 and PSMA.

Read More